This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the KarMMa Phase 2 Cohorts 2a and 2c Study Results of Abecma(idecabtagene vicleucel) in R/R multiple myeloma presented at the ASH 2022 conference
Ticker(s): TSVT, BMYWho's the expert?
Institution: Private Practice (Kenneth R. Hoffman, MD, MPH and Associates)
- Medical Oncologist and Cancer Epidemiologist in practice for 38 years with clinical and academic experience.
- knowledgable about most immuno-oncology therapeutics in development and the use of bispecific antibodies.
- Treats patients with NSCLC, ES-SCLC, breast cancer, DLBCL and many other oncologic/hematologic malignancies.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
